• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Developmental pharmacokinetics in pediatric populations.儿科人群的发育药代动力学。
J Pediatr Pharmacol Ther. 2014 Oct-Dec;19(4):262-76. doi: 10.5863/1551-6776-19.4.262.
2
Pharmacokinetics in the infant.婴儿的药代动力学。
Environ Health Perspect. 1994 Dec;102 Suppl 11(Suppl 11):107-10. doi: 10.1289/ehp.94102s11107.
3
Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I).新生儿药物生物处置的原则。药代动力学-药效学界面的批判性评价(第一部分)。
Clin Pharmacokinet. 1988 Apr;14(4):189-216. doi: 10.2165/00003088-198814040-00001.
4
Effect of maturation on drug disposition in pediatric patients.成熟对儿科患者药物处置的影响。
Clin Pharm. 1987 Jul;6(7):548-64.
5
Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults.儿科人群与成人之间药代动力学差异的因素和机制。
Pharmaceutics. 2011 Feb 7;3(1):53-72. doi: 10.3390/pharmaceutics3010053.
6
Clinical pharmacokinetics in infants and children. A reappraisal.婴幼儿临床药代动力学。重新评估。
Clin Pharmacokinet. 1989;17 Suppl 1:29-67. doi: 10.2165/00003088-198900171-00005.
7
Disposition and interaction of biotherapeutics in pediatric populations.儿科人群中生物疗法的处置和相互作用。
Curr Drug Metab. 2012 Sep 1;13(7):882-900. doi: 10.2174/138920012802138624.
8
Pharmacokinetic considerations in pediatric pharmacotherapy.儿科治疗药物动力学的考虑因素。
Am J Health Syst Pharm. 2019 Sep 16;76(19):1472-1480. doi: 10.1093/ajhp/zxz161.
9
Pharmacokinetics in children.儿童的药代动力学
J Antimicrob Chemother. 1994 Aug;34 Suppl A:19-24. doi: 10.1093/jac/34.suppl_a.19.
10
Developmental pharmacokinetics.发育药代动力学。
Semin Pediatr Neurol. 2010 Dec;17(4):208-13. doi: 10.1016/j.spen.2010.10.002.

引用本文的文献

1
Nanotechnological innovations in paediatric tuberculosis management: current trends and future prospects.儿科结核病管理中的纳米技术创新:当前趋势与未来前景
Front Drug Deliv. 2024 Jan 8;3:1295815. doi: 10.3389/fddev.2023.1295815. eCollection 2023.
2
Genomic and Cytotoxic Damage in Wistar Rats and Their Newborns After Transplacental Exposure to Hydroalcoholic Extract.经胎盘暴露于水醇提取物后Wistar大鼠及其新生仔鼠的基因组和细胞毒性损伤
Int J Mol Sci. 2025 Aug 1;26(15):7448. doi: 10.3390/ijms26157448.
3
A Novel Approach to Evaluating the Design of Pediatric Pharmacokinetic Studies Focused on Accurate Dose Selection.一种专注于准确剂量选择的儿科药代动力学研究设计评估新方法。
Clin Pharmacokinet. 2025 Jun 30. doi: 10.1007/s40262-025-01542-z.
4
Physiologically Based Pharmacokinetic Modeling of Antibiotics in Children: Perspectives on Model-Informed Precision Dosing.儿童抗生素的生理药代动力学建模:模型指导精准给药的观点
Antibiotics (Basel). 2025 May 24;14(6):541. doi: 10.3390/antibiotics14060541.
5
The Immature Infant Liver: Cytochrome P450 Enzymes and their Relevance to Vaccine Safety and SIDS Research.未成熟婴儿肝脏:细胞色素P450酶及其与疫苗安全性和婴儿猝死综合征研究的相关性
Int J Med Sci. 2025 Apr 28;22(10):2434-2445. doi: 10.7150/ijms.114402. eCollection 2025.
6
Who will be the bastions of pediatric trauma care?谁将成为儿童创伤护理的堡垒?
Trauma Surg Acute Care Open. 2025 May 10;10(Suppl 3):e001573. doi: 10.1136/tsaco-2024-001573. eCollection 2025.
7
Acute cannabis intoxication among the paediatric population.儿科人群中的急性大麻中毒。
Front Toxicol. 2025 Apr 14;7:1558721. doi: 10.3389/ftox.2025.1558721. eCollection 2025.
8
Navigating challenges in pediatric trial conduct: integrating bayesian sequential design with semiparametric elicitation for handling primary and secondary endpoints.应对儿科试验实施中的挑战:将贝叶斯序贯设计与半参数诱导相结合以处理主要和次要终点
BMC Med Res Methodol. 2025 Mar 31;25(1):82. doi: 10.1186/s12874-025-02484-7.
9
Refractory agitation in the NICU: challenges in prevention, diagnosis, and treatment.新生儿重症监护病房中的难治性躁动:预防、诊断及治疗中的挑战
Front Pediatr. 2025 Feb 27;13:1504619. doi: 10.3389/fped.2025.1504619. eCollection 2025.
10
Bayesian Population Pharmacokinetic Modeling of Ondansetron for Neonatal Opioid Withdrawal Syndrome.用于新生儿阿片类药物戒断综合征的昂丹司琼的贝叶斯群体药代动力学建模
Clin Transl Sci. 2025 Feb;18(2):e70147. doi: 10.1111/cts.70147.

本文引用的文献

1
Correlation-based prediction of tissue-to-plasma partition coefficients using readily available input parameters.使用易于获取的输入参数基于相关性预测组织-血浆分配系数
Xenobiotica. 2013 Oct;43(10):839-52. doi: 10.3109/00498254.2013.770182. Epub 2013 Feb 19.
2
Population pharmacokinetic analysis during the first 2 years of life: an overview.生命最初 2 年内的群体药代动力学分析:概述。
Clin Pharmacokinet. 2012 Dec;51(12):787-98. doi: 10.1007/s40262-012-0015-8.
3
Antibiotic dosing in children in Europe: can we grade the evidence from pharmacokinetic/pharmacodynamic studies - and when is enough data enough?欧洲儿童的抗生素剂量:我们能否对药代动力学/药效学研究的证据进行分级——以及何时数据足够?
Curr Opin Infect Dis. 2012 Jun;25(3):235-42. doi: 10.1097/QCO.0b013e328353105c.
4
Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development.基于生理的药代动力学建模:方法、应用及局限性,重点关注其在儿科药物研发中的作用
J Biomed Biotechnol. 2011;2011:907461. doi: 10.1155/2011/907461. Epub 2011 Jun 1.
5
Role of modeling and simulation in pediatric investigation plans.建模与仿真在儿科研究计划中的作用。
Paediatr Anaesth. 2011 Mar;21(3):214-21. doi: 10.1111/j.1460-9592.2011.03523.x. Epub 2011 Jan 18.
6
Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.在监管审查期间,生理基于药代动力学(PBPK)建模和模拟的应用。
Clin Pharmacol Ther. 2011 Feb;89(2):259-67. doi: 10.1038/clpt.2010.298. Epub 2010 Dec 29.
7
Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.基于生理学的药代动力学模型在儿科临床药理学中的应用复苏:整合生物学要素知识的平行转变以及在药物研发和临床实践中适用性的提高。
Paediatr Anaesth. 2011 Mar;21(3):291-301. doi: 10.1111/j.1460-9592.2010.03323.x.
8
Pharmacokinetic and pharmacodynamic basis for effective argatroban dosing in pediatrics.儿科有效阿加曲班给药的药代动力学和药效学基础。
J Clin Pharmacol. 2011 Jan;51(1):19-28. doi: 10.1177/0091270010365550. Epub 2010 Apr 26.
9
Identification of human UGT2B7 as the major isoform involved in the O-glucuronidation of chloramphenicol.鉴定人 UGT2B7 为参与氯霉素 O-葡萄糖醛酸结合反应的主要同工酶。
Drug Metab Dispos. 2010 Mar;38(3):368-75. doi: 10.1124/dmd.109.029900. Epub 2009 Dec 11.
10
Pediatric pharmacology in the first year of life.一岁以内小儿药理学
Curr Opin Anaesthesiol. 2009 Aug;22(4):469-75. doi: 10.1097/aco.0b013e32832bc7ff.

儿科人群的发育药代动力学。

Developmental pharmacokinetics in pediatric populations.

作者信息

Lu Hong, Rosenbaum Sara

机构信息

Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island.

出版信息

J Pediatr Pharmacol Ther. 2014 Oct-Dec;19(4):262-76. doi: 10.5863/1551-6776-19.4.262.

DOI:10.5863/1551-6776-19.4.262
PMID:25762871
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4341411/
Abstract

Information on drug absorption and disposition in infants and children has increased considerably over the past 2 decades. However, the impact of specific age-related effects on pharmacokinetics, pharmacodynamics, and dose requirements remains poorly understood. Absorption can be affected by the differences in gastric pH and stomach emptying time that have been observed in the pediatric population. Low plasma protein concentrations and a higher body water composition can change drug distribution. Metabolic processes are often immature at birth, which can lead to a reduced clearance and a prolonged half-life for those drugs for which metabolism is a significant mechanism for elimination. Renal excretion is also reduced in neonates due to immature glomerular filtration, tubular secretion, and reabsorption. Limited data are available on the pharmacodynamic behavior of drugs in the pediatric population. Understanding these age effects provide a mechanistic way to identify initial doses for the pediatric population. The various factors that impact pharmacokinetics and pharmacodynamics mature towards adult values at different rates, thus requiring continual modification of drug dose regimens in neonates, infants, and children. In this paper, the age-related changes in drug absorption, distribution, metabolism, and elimination in infants and children are reviewed, and the age-related dosing regimens for this population are discussed.

摘要

在过去20年里,有关婴幼儿和儿童药物吸收与处置的信息大幅增加。然而,特定年龄相关效应在药代动力学、药效学及剂量需求方面的影响仍知之甚少。吸收会受到儿科人群中观察到的胃pH值和胃排空时间差异的影响。低血浆蛋白浓度和较高的身体水分组成会改变药物分布。出生时代谢过程往往不成熟,这可能导致那些以代谢作为重要消除机制的药物清除率降低、半衰期延长。由于肾小球滤过、肾小管分泌和重吸收不成熟,新生儿的肾排泄也会减少。关于儿科人群中药物药效学行为的数据有限。了解这些年龄效应为确定儿科人群的初始剂量提供了一种机制性方法。影响药代动力学和药效学的各种因素以不同速率向成人值成熟,因此需要不断调整新生儿、婴儿和儿童的药物剂量方案。本文综述了婴幼儿和儿童药物吸收、分布、代谢和消除方面与年龄相关的变化,并讨论了该人群与年龄相关的给药方案。